CAS Space, Guangzhou Lab to Fly Space Pharma Payload on Lihong-2 in 2027

Space-pharma is a narrow but real niche, and pairing it with a reusable vehicle on a suborbital profile suggests the near-term goal is equipment validation rather than commercial manufacturing. The significance lies less in the experiments themselves than in the supply chain being assembled around them: a launch provider, a research institute, and a drug-discovery use case. Whether the crystallization results translate into terrestrial pipeline value, and whether reusable suborbital flights become a routine cadence for such payloads, are the open questions.